Second Division of Neurology, Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, Naples, Italy.
Mult Scler. 2023 Jun;29(7):779-788. doi: 10.1177/13524585221147635. Epub 2023 Jan 22.
Ocrelizumab is a humanized monoclonal antibody designed to bind to the CD20 molecule, resulting in a rapid depletion of B-cells; however, it has been shown that lymphocyte subpopulations other than B-cells are affected by the drug. To review the effects of ocrelizumab on circulating lymphocytes and identify candidate biomarkers to predict and monitor treatment response. A literature search for the most relevant articles from 2006 to 2022 was conducted in PubMed and Scopus. The effect of ocrelizumab on the peripheral immune system goes beyond B-cells; it also depletes T CD20 + lymphocytes. Further, ocrelizumab reshapes the T-cell response toward a low inflammatory profile and induces an increase in T CD8 + regulatory cell percentage. A higher Body Mass Index and higher B-cell count at baseline have been associated with early B-cell reappearance. Serum neurofilament light chain reduction has been associated with treatment response. Ocrelizumab treatment exerts a broad immunomodulatory effect and may be tailored based on patients' clinical and biological profiles.
奥瑞珠单抗是一种人源化单克隆抗体，旨在与 CD20 分子结合，导致 B 细胞迅速耗竭；然而，已经表明，除了 B 细胞以外，淋巴细胞亚群也受到药物的影响。为了综述奥瑞珠单抗对循环淋巴细胞的影响，并确定预测和监测治疗反应的候选生物标志物。在 PubMed 和 Scopus 中进行了 2006 年至 2022 年最相关文章的文献检索。奥瑞珠单抗对外周免疫系统的影响超出了 B 细胞；它还耗竭了 T CD20+淋巴细胞。此外，奥瑞珠单抗使 T 细胞反应向低炎症特征重塑，并诱导 T CD8+调节性细胞百分比增加。较高的体重指数和基线时较高的 B 细胞计数与早期 B 细胞重现有关。血清神经丝轻链减少与治疗反应相关。奥瑞珠单抗治疗产生广泛的免疫调节作用，并且可以根据患者的临床和生物学特征进行调整。
